Research models and services blog posts

12 January, 2018

8 insightful Envigo antibody resources from 2017

By John Kennett

Maximize your research, diagnostic or therapeutic use of antibodies in 2018 and beyond

It was a busy year for Envigo’s custom antibodies team in 2017.  As another year came to an end, we collated a round-up of the top 8 insightful materials that were published by the team throughout last year.  We hope these will help you maximize your research, diagnostic or therapeutic use of antibodies in 2018 and beyond.

Wishing you a prosperous 2018!

+ Read more
 

21 December, 2017

Imagine a world without antibodies

By John Kennett

Ongoing efforts to advance research, diagnostics and therapeutic products

It is hard to imagine a world without antibodies. Besides their natural ability to fight off diseases in animals, they are widely used by the scientific community as research and development tools. Antibodies, both polyclonal (pAb) and monoclonal (mAb), are well established and versatile reagent tools for the study of a wide variety of biological functions, 3D structure analysis, metabolic pathways studies, in vivo imaging, cell modulation, and quantification of a host of analytes. They are also used as therapeutic drugs and are amongst the biggest selling therapeutics making a significant difference to patients’ lives.

+ Read more
 

18 December, 2017

How do you intend to use your antibody?

By John Kennett

Antigen selection and preparation

Optimal selection and preparation of the antigen is crucial to obtaining high-quality antibodies in both polyclonal and monoclonal antibody production. Although the importance of antigen selection and preparation is not immediately apparent to some in the field, Envigo’s experience has shown that it is a critical consideration.

+ Read more
 

23 November, 2017

Antibody reproducibility: the importance to your research

By Richard Harrison

The production of antibodies for use in research and development and in medicine has a long history. Although there is no doubt that the use of antibodies has made a significant contribution to our basic understanding of biology, they have also been singled out as a major factor in the poor reproducibility of many biology-based studies.

+ Read more
 

22 November, 2017

Best practices for bridging studies to generate data and validate a new strain

By Travis Rothrock

In this final blog on bridging studies, we provide general best-practices relevant to oncology bridging studies, including basic study design considerations and insights that are the culmination of many years of hands-on experience by Envigo experts.

+ Read more
 

22 November, 2017

The importance of bridging studies when switching strains

By Travis Rothrock

Bridging studies play an important role in drug development, both in the clinical and preclinical stages. These studies provide important information that can circumvent the repetition of entire programs. Understanding the considerations and steps in switching rodent strains and the importance of bridging studies, is critical. In this post we outline the best practices on bridging studies.

+ Read more
 

22 November, 2017

Bridging studies - Why do researchers switch rodent strains?

By Travis Rothrock

Selecting the right model and rodent strain for your oncology studies can maximize the chances of success. However, there is an ever-increasing portfolio of available models and strains that may perform better than existing ones and may be more optimal for specific study purposes.

Increasing investigators are seeking to bridge from an existing rodent strain to another for their oncology preclinical efficacy and pharmacology studies. The short-term barriers associated with switching strains can appear complex and daunting, but another strain may actually be the key to the success of your oncology preclinical program.

Be sure to understand how you can benefit from switching to a new oncology rodent strain.

+ Read more
 

22 August, 2017

5 easy ways to avoid antibody production mistakes

By Richard Drucker

Creating highly productive cell lines requires a great level of care that starts with cell line development. Envigo’s Rook Khajenouri and Richard Drucker understand the challenges customers face throughout the process. They recently discussed some common production problems and offered solutions for ensuring consistent and reliable results that enhanced antibody production.

+ Read more
 

13 July, 2017

5 Tips to successful monoclonal antibody production

By Richard Harrison

Monoclonal antibodies play a critical role in research, diagnostics and product development and provide numerous benefits to patients in diverse therapeutic areas.

mAbs are capable of recognizing only one epitope found on an antigen. Therefore they have greater specificity than polyclonal antibodies (pAbs), which makes them ideal for diagnostic and therapeutic uses. Custom monoclonal antibody production requires a different skillset than polyclonal antibody production, and often results in additional costs and time.

The specificity of mAbs has made them ideal for medical applications such as diagnostic and therapeutic use. So what are the key considerations in the production of monoclonal antibodies?

+ Read more
 

23 June, 2017

6 simple secrets for polyclonal antibody production

By Richard Harrison

Careful planning and preparation is essential to produce exceptional polyclonal antibodies (pABs). Polyclonal antibodies are produced from a mixture of B lymphocytes with different epitope affinities toward the same antigen. From start to finish, pAb development takes two to six months, though custom schedules may take more time.
The first step is to select the immunizing antigen. pAbs are not suitable for some applications and monoclonal antibodies (mAbs) may be more appropriate, as discussed in the next blog article.

The first step is to select the immunizing antigen. pAbs are not suitable for some applications and monoclonal antibodies (mAbs) may be more appropriate, as discussed in the next blog article.

+ Read more